...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma.
【24h】

Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma.

机译：晚期肝细胞癌动脉灌注化疗疗效与P-糖蛋白和p53蛋白表达的关系。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM:To investigate the relationship between the chemotherapeutic drug efficacy and the expression of P-glycoprotein (PGP) and p53 protein in advanced hepatocellular carcinoma (HCC).METHODS:The study was conducted on 41 patients with advanced HCC who were treated by repeated arterial infusion chemotherapy. Biopsy specimens from the tumor were collected before the start of treatment in all the patients, and the specimens were stored frozen until immunohistochemical staining, which was performed after the start of treatment, to detect PGP and p53 protein expressions. Twenty of the forty-one patients were treated with an anthracycline drug (epirubicin hydrochloride; anthracycline group), and the remaining 21 were treated with a non-anthracycline drug (mitoxantrone hydrochloride in 11 patients and carboplatin in 10 patients; non-anthracycline group). The relationship between the chemotherapeutic efficacy and the results of immunostaining were compared between the two groups.RESULTS:Before the start of the treatment, PGP-positive rate was 90.2% (strongly-positive, 36.6%) and p53 protein-positive rate was 34.1% (strongly-positive, 19.5%). In the anthracycline group, the response rate was 40.0%. The number of patients showing poor response to the treatment was significantly larger in the patients with strongly positive PGP expression (P=0.005), and their prognoses were poor (P=0.001). In the non-anthracycline group, the response rate was 42.9%, and there was no significant relationship between the chemotherapeutic drug efficacy and the PGP or p53 protein expression. When only the data from the 11 patients treated with anthraquinone drug, mitoxantrone, were analyzed, however, the number of patients who showed poor response to treatment was significantly higher among the p53-positive patients (P=0.012), irrespective of the survival outcome.CONCLUSION:The chemotherapeutic efficacy with an anthracycline drug for advanced HCC can be predicted by immunohistochemical analysis of PGP expression. Similarly, immunostainingto evaluate p53 protein may be useful to predict the response in patients treated with an anthraquinone drug.
机译：目的：探讨晚期肝细胞癌（HCC）化疗药物疗效与P-糖蛋白（PGP）和p53蛋白表达之间的关系。方法：本研究针对41例经反复动脉治疗的晚期HCC患者输液化疗。在所有患者开始治疗之前，从肿瘤中收集活检标本，并将标本冷冻保存直至开始治疗后进行免疫组织化学染色，以检测PGP和p53蛋白的表达。 41名患者中有20名接受了蒽环类药物治疗（盐酸厄比霉素；蒽环类药物治疗组），其余21名接受了非蒽环类药物治疗（盐酸米托蒽醌治疗11例，卡铂治疗10例；非蒽环类药物治疗） 。结果：治疗开始前，PGP阳性率为90.2％（强阳性，为36.6％），p53蛋白阳性率为34.1。 ％（强阳性，19.5％）。蒽环类药物治疗组的缓解率为40.0％。在PGP表达强烈阳性的患者中，对治疗反应较差的患者人数明显增多（P = 0.005），并且其预后较差（P = 0.001）。在非蒽环类药物治疗组中，有效率为42.9％，化疗药物疗效与PGP或p53蛋白表达之间无显着相关性。仅分析了接受蒽醌药物米托蒽醌治疗的11例患者的数据时，p53阳性患者中对治疗反应较差的患者数量明显更高（P = 0.012），而与生存结果无关结论：可以通过免疫组织化学分析PGP的表达来预测蒽环类药物对晚期肝癌的化疗疗效。同样，免疫染色评估p53蛋白可能有助于预测蒽醌类药物治疗患者的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号